Definitive Contract HHSD200201796178C
Award Date 9/30/17
Potential Completion Date 9/28/19
Potential Value $499K
Federal Agency
Ultimate Awardee
Not listed Federal Contract Vehicle
- Not listed
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed Pricing Type
Firm Fixed Price
Place of Performance
University City, MO 63130, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
127
Legislative Mandate
Not listed National Interest Action
Not listed Research Type
Not listed Primary Consortia Member
Not listed Similar Awards
- The Washington University Office of Sponsored Research Services Division has been awarded a definitive contract valued at $748,687 by the Centers for Disease Control and Prevention (CDC) in Atlanta, Georgia. The contract is associated with CDC's Fiscal Year 2021 Broad Agency Announcement Topic 4.4 and will support the agency's public health programs. As a firm fixed price contract, Washington University will provide specified products or services to the CDC over a thirty-month period ending...
- The Centers for Disease Control and Prevention (CDC) awarded a $618,826.91 firm fixed price purchase order to The Washington University Office of Sponsored Research Services Division as the prime contractor. The contract is for one year of performance from September 30, 2023 through September 29, 2024 to support the CDC's research programs. As the prime, Washington University will leverage its expertise conducting federally-funded public health research. No subcontractors or additional context...
- This is a $490,499 firm fixed-price contract awarded by the Centers for Disease Control and Prevention (CDC) to The Washington University, a private research university in St. Louis, Missouri. The contract is for an "Early Life Antibiotic Therapy Study" and does not have a set-aside designation. The Washington University has extensive experience as a prime contractor and subcontractor on federal research and development contracts and grants with agencies such as the Department of...
- The U.S. Centers for Disease Control and Prevention (CDC) awarded a $499,983 firm-fixed-price contract to The Washington University in St. Louis, Missouri for COVID-19 related research under the FY 2020 COVID-19 Broad Agency Announcement (BAA) Topic 1. The contract does not have a small business set-aside designation. The Washington University, a private research university, has extensive experience partnering with federal agencies like the Department of Defense, Department of Veterans...
- This $498,427 firm fixed-price federal contract was awarded by the Centers for Disease Control and Prevention (CDC) to The Washington University, a private research university based in St. Louis, Missouri. The contract is for an "Intestinal Metabolic Factors Study" and does not have a set-aside designation. The Washington University has extensive experience as a prime contractor on federal research and development projects for various government agencies, including the Department of...
- The Department of Health and Human Services Centers for Disease Control and Prevention awarded a $256,309 firm fixed price contract to The Washington University. This contract was awarded under Broad Agency Announcement Number 75D301-20-R-68024, which solicited white papers related to developing strategies for protecting communities from COVID-19 through research projects addressing topics such as virus transmission, sequencing, and controlling spread. The Washington University will determine...
- This is a $305,317 firm fixed-price contract awarded by the Centers for Disease Control and Prevention (CDC) to The Washington University, a private university in St. Louis, Missouri, to conduct research on "METABOLIC MICROBIOME DISRUPTION". The contract has a completion date of September 25, 2023 and was awarded on September 26, 2022. This award does not have a set-aside designation. The Washington University has a long history of performing research and specialized services for...
- This is a $456,310 firm fixed-price contract awarded by the Centers for Disease Control and Prevention (CDC) to The Washington University in St. Louis, Missouri. The contract was awarded under the FY 2020 COVID-19 Broad Agency Announcement (BAA) Topic 2 and has a completion date of July 15, 2022. The contract is for research and services related to the COVID-19 pandemic, but no set-aside designation is mentioned. The Washington University is a private university with extensive experience in...
- This is a $307,910 firm-fixed-price definitive contract awarded by the Centers for Disease Control and Prevention (CDC) to The Washington University, a private university in St. Louis, Missouri. The contract is for the "MODEL MICROBIOME UWSL" project, with a period of performance ending on March 29, 2023. The contract is not set aside for any specific business category. The Washington University has a history of providing a wide range of research, education, and specialized services to...
- The Department of Health and Human Services Centers for Disease Control and Prevention awarded a firm fixed price purchase order to The Washington University Office Of Sponsored Research Services Division, a private university, to conduct research on "Imaging of Particle-Induced Lung Inflammation." The $32,400 contract has a performance period ending on March 31, 2025 and will be performed in St. Louis, Missouri. The Washington University has a history of providing research,...
The Washington University Office of Sponsored Research Services Division was awarded a definitive contract valued at approximately $499,305 by the Centers for Disease Control and Prevention (CDC) to conduct a toxicology study on negative health effects. The contract was awarded under the CDC's Pittsburgh office and will be performed by the prime contractor in University City, Missouri over a two year period from September 2017 through September 2019. No additional details were provided on subcontractors or the specific study to be conducted. The award is firm fixed price and falls under the CDC's broader efforts to research and prevent disease.
Generated 12/31/23, 9:08 AM
Name | Description | Solicitation Number | FederalAgency | Type | PostedDate |
|---|---|---|---|---|---|
Double blinded, randomized controlled Trial of Oral vancomycin versus placebo in hospitalized patients with diarrhea and stool toXin NEGative but nucleic acid amplification test positive for toxigenic Clostridium difficile (TOX NEG trial) | CDCBAAFY2017-OADS-01-96178 | Department of Health and Human Services Centers for Disease Control and Prevention Office of Acquisition Services | Award Notice 1/1 | 10/7/17, 10:10 PM |
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| 2 | Other Administrative Action | $0 | 12/30/23 | |
| 1 | Supplemental Agreement for work within scope | $0 | 8/19/18 | |
| Not listed | Not listed | $499.3k | 9/19/17 |